Mark Kieran

Mark Kieran has a strong background in the medical and biopharmaceutical industry. Mark started their career in 1997 at the Dana-Farber Boston Children's Blood and Cancer Center, where they served as the Director of Pediatric Neuro-Oncology for over 20 years until 2018. Following their role at Dana-Farber, Mark joined Bristol Myers Squibb as the Pediatric Clinical Trial Lead. In 2021, they transitioned to Day One Biopharmaceuticals, taking on the position of VP, Clinical Development.

Mark Kieran began their education in 1970 at McMaster University, where they obtained a Bachelor of Science degree in Biochemistry in 1975. Following this, they attended the University of Alberta from 1980 to 1983, earning a Doctor of Philosophy degree in Immunology. From 1983 to 1986, they pursued their medical studies at the University of Calgary, School of Medicine, obtaining a Doctor of Medicine degree. Mark then went on to complete a Postdoctoral Fellowship in Molecular Biology at the Pasteur Institute from 1986 to 1989. Mark continued their education at McGill University from 1989 to 1992, specializing in Pediatric residency. Subsequently, they pursued a Pediatric Hematology/Oncology Fellowship at Harvard Medical School - Boston Children's Hospital from 1992 to 1995. Lastly, from 1993 to 1997, Mark completed a Post-Doctoral Fellowship in Signal Transduction at Harvard Medical School.